pmn310
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2023 (NCT06105528)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Amyloid beta A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06750432 | Phase 1 | Dec 13, 2024 | CenExel iResearch, LLC, ProMis Neurosciences, Inc |
| NCT06105528 | Phase 1 | Nov 18, 2023 | OCT Clinical Trials, ProMis Neurosciences, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ProMis Neurosciences, Inc | For profit | 2 | 2 | 1 | 2023 |
| CenExel iResearch, LLC | For profit | 1 | 0 | 1 | 2024 |
| OCT Clinical Trials | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1